BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26

• Press Releases

  Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

  May 5, 2026

   · 

  28 min read
• Press Releases

  Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

  May 5, 2026

   · 

  20 min read
• Press Releases

  Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

  May 5, 2026

   · 

  11 min read
• Press Releases

  Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

  May 5, 2026

   · 

  10 min read
• Press Releases

  Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

  May 5, 2026

   · 

  13 min read
• Press Releases

  Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

  May 5, 2026

   · 

  4 min read
• Press Releases

  Longwood Healthcare Leaders to Host MIT CEO, Off-the-Record Networking and Discussion Forum, Convening Life Science Thought Leaders at MIT Koch Institute

  May 5, 2026

   · 

  3 min read
• Press Releases

  FDA Grants Fast Track Designation for CS-1103, a First-in-class Small Molecule to Reverse Acute Intoxication from Fentanyl

  May 5, 2026

   · 

  2 min read
• Press Releases

  Neuronetics Reports First Quarter 2026 Financial and Operating Results

  May 5, 2026

   · 

  16 min read
• Press Releases

  Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

  May 5, 2026

   · 

  13 min read